Millennium Management LLC Sells 77,322 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Millennium Management LLC lowered its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 21.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 284,123 shares of the company's stock after selling 77,322 shares during the quarter. Millennium Management LLC owned 15.19% of Tonix Pharmaceuticals worth $94,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC grew its position in Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after purchasing an additional 1,855,907 shares during the period. Jane Street Group LLC boosted its holdings in Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock worth $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals during the 4th quarter worth $162,000. Finally, Commonwealth Equity Services LLC purchased a new position in Tonix Pharmaceuticals during the 4th quarter worth $40,000. Institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock traded down $2.56 during trading on Friday, reaching $31.98. 680,544 shares of the company's stock traded hands, compared to its average volume of 922,491. The company has a market capitalization of $234.25 million, a P/E ratio of -0.01 and a beta of 2.09. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm's 50-day moving average is $25.07 and its 200 day moving average is $23.59. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $6.76 and a 1 year high of $137.25.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.43 million for the quarter, compared to analysts' expectations of $2.55 million. Equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Noble Financial reaffirmed an "outperform" rating and set a $70.00 price objective on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. Wall Street Zen raised shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd.

Insider Activity

In related news, CEO Seth Lederman acquired 4,000 shares of the stock in a transaction dated Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the transaction, the chief executive officer now owns 4,005 shares in the company, valued at $86,307.75. This represents a 80,000.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.03% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.